Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | PRKCG | P05129 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.40 |
| ▸ | PRKX | P51817 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16539996 | 0.99 | CASR (0.41) | CASRFFAR1ROCK1ROCK2CYP2C9 | |
| SCHEMBL16548235 | 0.94 | CASR (0.39) | CASRFFAR1ROCK1ROCK2CYP2C9 | |
| SCHEMBL16548234 | 0.93 | POLB (0.41) | CASRFFAR1ROCK1ROCK2CYP2C9 | |
| SCHEMBL16541124 | 0.93 | POLB (0.41) | CASRFFAR1ROCK1ROCK2CYP2C9 | |
| Hydrochloric Acid SCHEMBL17939882 | 0.93 | CASR (0.39) | CASRFFAR1ROCK1ROCK2CYP2C9 | |
| Hydrochloric Acid SCHEMBL16540625 | 0.92 | POLB (0.41) | CASRFFAR1ROCK1ROCK2CYP2C9 | |
| SCHEMBL17945191 | 0.92 | PTGS2 (0.41) | FFAR1ROCK1PRKACAGSK3AGSK3B | |
| SCHEMBL18215341 | 0.92 | PTGS2 (0.41) | FFAR1ROCK1PRKACAGSK3AGSK3B | |
| SCHEMBL17945890 | 0.91 | CASR (0.41) | CASRFFAR1ROCK1ROCK2PRKACA | |
| SCHEMBL18215342 | 0.91 | CASR (0.41) | CASRROCK1ROCK2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493396-B2 | Substituted naphthalene compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493396-B2 | Substituted naphthalene compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20160214924-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-07-28 | — | — | US | disclosed |
| US-20160214924-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-07-28 | — | — | US | disclosed |
| WO-2015028938-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214924-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, RYR1 | CASR 1/4885FFAR1 110/4885ROCK1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.